<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568980</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008095</org_study_id>
    <nct_id>NCT04568980</nct_id>
  </id_info>
  <brief_title>Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis</brief_title>
  <acronym>CASE4CF</acronym>
  <official_title>Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis: A Retrospective Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long-term goal is to study the safety and effectiveness of hormonal contraception for&#xD;
      women with cystic fibrosis (CF) and contribute to national guidelines that the Cystic&#xD;
      Fibrosis Foundation and the Centers for Disease Control and Prevention (CDC) provide to&#xD;
      clinicians. The study objectives are to determine whether hormonal contraceptive methods&#xD;
      improve overall pulmonary health, worsen CF-related disease or CF liver disease, or are&#xD;
      effective against unwanted pregnancy with concomitant CF transmembrane conductance regulator&#xD;
      (CFTR) modulator use. The hypothesis is that hormonal contraceptive methods are safe and do&#xD;
      not worsen CF-related complications over time,improve FEV-1 when compared to non-hormonal&#xD;
      users, and oral birth control methods with CFTR modulator use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional, observational cohort design among&#xD;
      reproductive-aged women (ages 18-45 years) with CF. The investigators intend to ask about 625&#xD;
      female participants to provide information about their types of past contraceptive use from&#xD;
      2008 through the most recent data available from CFFPR (2018 or 2019). Before initiating our&#xD;
      trial among up to 625 respondents, the investigators intend to pre-test the survey questions&#xD;
      on our self-respondent questionnaire among as many as 50 women with and without CF through&#xD;
      CFF Community Voice, the Cystic Fibrosis Research, Inc. (CFRI), and the Cystic Fibrosis&#xD;
      Reproductive and Sexual Health Collaborative (CFReSHC). Pre-testing the study survey&#xD;
      questions will help ensure contraceptive, pregnancy, and other reproductive health data from&#xD;
      respondents for the larger phase of this study are as complete and accurate as possible. Once&#xD;
      the survey has been piloted and revised accordingly, the investigators will collect past&#xD;
      contraceptive, pregnancy and other reproductive health data from up to 625 women at 10&#xD;
      different CF centers. The investigators may over-sample by 25 participants because it is&#xD;
      possible that some participants from UW, UTSW and National Jewish may have participated an&#xD;
      earlier published study related to contraceptive use and CFFPR. Recruiting through the CF&#xD;
      centers will help ensure that women with a confirmed diagnosis of CF respond to the finalized&#xD;
      survey. The investigators will link respondent self-reported contraceptive and reproductive&#xD;
      health data with CFFPR clinical data. The investigators will ask for EMR data from the 10&#xD;
      different CF centers to validate DXA scan results with findings regarding osteoporosis,&#xD;
      osteopenia, and bone fracture in the CFFPR. The investigators plan to randomly select about&#xD;
      10 consented subjects from each of the centers for the EMR DXA scan chart review. Because of&#xD;
      the need to link questionnaires and clinical case report forms correctly to the same women&#xD;
      with CF in the CFFPR clinical data, this study requests identifiable information, including&#xD;
      the CFFPR member ID number.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary exacerbations</measure>
    <time_frame>2010-2018</time_frame>
    <description>Annual pulmonary exacerbation rate (PEx) (defined as episodes requiring intravenous antibiotic use at home or in hospital)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>2010-2018</time_frame>
    <description>Absolute change in FEV1 (in liters) measurements over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolism</measure>
    <time_frame>2010-2018</time_frame>
    <description>Incidence of venous or arterial thromboembolism. Noted on self-respondent survey (defined as blood clot requiring anticoagulation treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver dysfunction</measure>
    <time_frame>2010-2018</time_frame>
    <description>Incidence of gallstones requiring surgery, hepatic steatosis, hepatic cirrhosis and/or increased liver enzyme test values (ALT/GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose trends</measure>
    <time_frame>2010-2018</time_frame>
    <description>Incidence of insulin resistance or time to CF-related diabetes requiring insulin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>2010-2018</time_frame>
    <description>BMI trends</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone health</measure>
    <time_frame>2013-2018</time_frame>
    <description>DXA scan determination of osteopenia or osteoporosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unintended pregnancy</measure>
    <time_frame>2010-2018</time_frame>
    <description>Absolute number of self-reported unplanned pregnancies. We will also correlate date of reported unplanned pregnancy with dates of taking a CFTR modulator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudomonas aeruginosa</measure>
    <time_frame>2010-2018</time_frame>
    <description>Rate of conversion from non-mucoid to mucoid P. aeruginosa</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">625</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Hormonal contraceptive users</arm_group_label>
    <description>Persons exposed to any hormonal method of birth control. This includes combined oral contraceptive pills, combined transdermal patch, combined vaginal ring, progestin-only pills, depo-medroxyacetate, levonorgestrel intrauterine system/device, hormonal subdermal implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-hormonal contraceptive users</arm_group_label>
    <description>Persons exposed to any non-hormonal method of birth control. This includes male or female sterilization methods, Copper intrauterine device, internal/external condoms, diaphragm, cervical cap, withdrawal, sponge, fertility based methods, spermicide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-contraceptive users</arm_group_label>
    <description>Persons who did not use any method of birth control</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women with cystic fibrosis who have not used any form of contraception, or who have used&#xD;
        contraception for protection against pregnancy or for treatment of dysmenorrhea, pelvic&#xD;
        pain, abnormally heavy or prolonged menstrual bleeding, endometriosis, acne or amenorrhea.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with cystic fibrosis age 18-45 years&#xD;
&#xD;
          -  Enrolled as a participant of the Cystic Fibrosis Foundation Patient Registry&#xD;
&#xD;
          -  Working email address&#xD;
&#xD;
          -  Can read written English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Does not have a phone number or email address in their record&#xD;
&#xD;
          -  &lt;18 years or &gt;45 years at enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily M Godfrey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Ruben, MPH</last_name>
    <phone>206-685-3276</phone>
    <email>mruben@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily M Godfrey, MD</last_name>
    <phone>206-685-4895</phone>
    <email>godfreye@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigrid Ladores, PhD</last_name>
      <email>sladores@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheila Mody, MD</last_name>
      <email>smody@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Douglas Conrad, MD</last_name>
      <email>dconrad@ucsd.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Taylor-Cousar, MD</last_name>
      <email>TaylorCousarJ@njhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie West, MD</last_name>
      <email>nwest5@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital/Harvard</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmet Uluer, MD</last_name>
      <email>Ahmet.Uluer@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Walker, MD</last_name>
      <email>Patricia.Walker@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Elinor Schwind, MS</last_name>
      <email>Elinor.Schwind@mountsinai.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Roe, MD</last_name>
      <email>Andrea.Roe@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Traci Kazmerski, MD</last_name>
      <email>Traci.Kazmerski@chp.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raksha Jain, MD</last_name>
      <email>raksha.jain@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moira L Aitken, MD</last_name>
      <phone>206-543-3166</phone>
      <email>moira@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Emily Godfrey</investigator_full_name>
    <investigator_title>Associate Professor, School of Medicine</investigator_title>
  </responsible_party>
  <keyword>birth control</keyword>
  <keyword>contraception</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>CFTR modulator</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04568980/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

